{"id":529787,"date":"2021-02-10T19:36:01","date_gmt":"2021-02-10T19:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=529787"},"modified":"2021-02-10T19:36:01","modified_gmt":"2021-02-10T19:36:01","slug":"venous-leg-ulcer-market-size-share-trends-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/venous-leg-ulcer-market-size-share-trends-leading-companies-emerging-drugs-and-epidemiology-forecast_529787.html","title":{"rendered":"Venous Leg Ulcer Market Size, Share, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast"},"content":{"rendered":"
\"Venous<\/a><\/p>\n
\n
Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Venous Leg Ulcer Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Venous Leg Ulcer, historical and forecasted epidemiology as well as the Venous Leg Ulcer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

A venous leg ulcer (VLU)<\/strong> is defined as the loss of skin below the knee on the leg or foot in the presence of venous disease. These ulcers persist for more than 6 weeks and are therefore referred to as chronic venous leg ulcers<\/strong>, representing the most advanced form of chronic venous disorders like varicose veins and lipodermatosclerosis.<\/p>\n

Risk factors for Venous Leg Ulcer<\/strong> include older age, obesity, trauma, immobility, congenital absence of veins, deep vein thrombosis (DVT), phlebitis, and factor V Leiden mutation. The cornerstone of the diagnosis of chronic venous insufficiency<\/strong> includes demonstrating venous disease. The clinician must rule out the significant coexisting arterial disease by performing a thorough clinical assessment and obtaining an ankle-brachial pressure index.<\/p>\n

Venous Leg Ulcer has a negative impact on the quality of life and results in considerable costs to both patients and healthcare providers. Also, there are no uniform guidelines for the assessment and management of this group of conditions, which is reaching epidemic proportions in prevalence.<\/strong><\/p>\n

Get FREE sample copy at: <\/strong>
https:\/\/www.delveinsight.com\/sample-request\/venous-leg-ulcer-market<\/a><\/strong><\/p>\n

The Venous Leg Ulcer market report<\/strong> also covers emerging drugs, current treatment practices, Venous Leg Ulcer market share of the individual therapies, current and forecasted Venous Leg Ulcer Market Size from 2017 to 2030 segmented by seven major markets. <\/p>\n

The report provides a detailed current Venous Leg Ulcer treatment practice<\/strong>\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. <\/p>\n

\"Venous<\/p>\n

Venous Leg Ulcer Market Key Facts<\/strong><\/p>\n

Among 7MM, the United States accounted for the highest market size of venous leg ulcers in comparison to EU5 and Japan in 2017.<\/strong><\/p>\n

Venous ulcers (VUs) account for approximately 75% of all chronic leg ulcers<\/strong> and are characterized by several factors that hinder and delay healing. According to a study by Nelson et al. (n.d.) between 1.5\/1,000 and 3.0\/1.000 people have active leg ulcers and prevalence increases with age to about 20\/1,000 people aged over 80 years.<\/p>\n

Venous leg ulceration<\/strong> occurs secondary to venous reflux or obstruction. It affects up to 3 in 1,000 people (Nelson et al.).<\/p>\n

Leg ulcers are usually secondary to venous reflux or obstruction, but 20% of persons with leg ulcers have arterial disease, with or without venous disorders.<\/p>\n

According to the NHS, venous leg ulcer<\/strong> is the most common type of leg ulcer, accounting for more than 90% of all cases.<\/p>\n

Key Benefits of Venous Leg Ulcer Market Report<\/strong><\/p>\n